Previous close | 42.01 |
Open | 42.20 |
Bid | 43.76 x 600 |
Ask | 43.88 x 1300 |
Day's range | 41.30 - 43.89 |
52-week range | 31.86 - 45.00 |
Volume | |
Avg. volume | 1,018,957 |
Market cap | 5.578B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 20.87 |
EPS (TTM) | 2.10 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 51.78 |
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2024 Earnings Call Transcript May 7, 2024 Halozyme Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. My name is [Perla] (ph), and I’ll be your conference operator today. […]
Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences: